Mesoblast Ltd has released a press release.
Durable Three Year Outcomes in Disc Disease
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Mesoblast
- FDA Grants Mesoblast Fast Track Designation For GVHD
- Positive Nine Month RA Results For Mesoblast Cell Therapy
- Published Results Show MSB Cells Effective In RA Model
- Mesoblast Director Recognized For Cardiovascular Leadership
- Mesoblast And Mallinckrodt Enter Into Agreement
Later from Mesoblast
- Mesoblast Raises US$40 Million
- Process Initiated For CHF P3 Interim Analysis
- FDA Clears Heart Disease Trial At Boston Childrens Hospital
- Mesoblast Receives A$3.7m From Aus Govt For R&D
- Successful Interim Analysis in Phase 3 Heart Failure Trial
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast